Long-Term Infectious and Noninfectious Outcomes of Monthly Alemtuzumab as a Calcineurin Inhibitor- and Steroid-Free Regimen for Pancreas Transplant Recipients

<div>Cumulative incidence of survival. EAE: extended alemtuzumab exposure; SIM: standard induction and maintenance therapy.</div>

Canadian Journal of Infectious Diseases and Medical Microbiology

fig4

Figure 4

Figure 4: Long-Term Infectious and Noninfectious Outcomes of Monthly Alemtuzumab as a Calcineurin Inhibitor- and Steroid-Free Regimen for Pancreas Transplant Recipients 

Figure 4 | Long-Term Infectious and Noninfectious Outcomes of Monthly Alemtuzumab as a Calcineurin Inhibitor- and Steroid-Free Regimen for Pancreas Transplant Recipients 